Skip to content

A Randomized Controlled Trial for Qing Jin Yi Qi granule in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia(COVID-19)

A Randomized Controlled Trial for Qing Jin Yi Qi granule in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia(COVID-19)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043045
Enrollment
Unknown
Registered
2021-02-04
Start date
2021-01-29
Completion date
Unknown
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Shijiazhuang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Conform to the diagnostic criteria of COVID-19(Guidelines for the diagnosis and treatment of coronavirus disease 2020(trial version eighth))Patients who met the discharge standard and had negative neocoronavirus nucleic acid detection after discharge 2) Aged 18-75 years; 3) Having clinical manifestations of respiratory symptoms or fatigue; 4) Patient informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients who have undergone operations that affect lung function, such as lung transplantation, lung resection, lung volume reduction, etc; 2) Dependent on mechanical ventilation to maintain lung function, such as ventilator; 3) Combined with chronic lung diseases that affect lung function, such as severe chronic obstructive pulmonary disease; 4) Patients with heart function related diseases, such as heart failure and pacemaker installation; 5) Severe underlying diseases affecting survival, including uncontrolled heart, kidney, digestive, blood diseases, neuropsychiatric diseases, immune diseases, metabolic diseases, malignant tumors, severe malnutrition, etc; 6) Resting heart rate > 120 / min; 7) Systolic blood pressure > 180mmhg, diastolic blood pressure > 100mmhg; 8) Unstable angina pectoris or myocardial infarction in recent 1 month; 9) Severe obesity (BMI > 30 kg / m2); 10) Allergic constitution, allergic to the drug components involved in the treatment program; 11) Pregnant or lactating women; 12) Disabled people who can't complete the collection of efficacy evaluation indicators; 13) Mental state can not cooperate, suffering from mental illness, no self-control, can not express clearly; 14) Participants in other clinical trials; 15) According to the judgment of the researchers, there will be patients with complications or poor compliance that affect the efficacy and safety evaluation.

Design outcomes

Primary

MeasureTime frame
Visual analogue scale for cough;modified Medical Research Council Dyspnea Scale (MMRC);Borg perceived fatigue scale;

Secondary

MeasureTime frame
TCM syndrome score;Depression Scale (PHQ-9), anxiety scale (GAD-7);Blood oxygen saturation;6 minutes walking distance;Chest CT;Immune inflammation index;

Countries

China

Contacts

Public ContactZhao Yubin, Dai Erhei

Shijiazhuang People's Hospital

drzhyubin@163.com+86 19932101717

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026